{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-like+peptide-1",
    "query": {
      "intervention": "Glucagon-like peptide-1"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 659,
    "total_pages": 66,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-like+peptide-1&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T05:03:43.599Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03936049",
      "title": "Replication of the LEADER Diabetes Trial in Healthcare Claims",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Liraglutide",
          "type": "DRUG"
        },
        {
          "name": "DPP-4 inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "50 Years to 120 Years"
      },
      "enrollment_count": 168690,
      "start_date": "2017-09-22",
      "completion_date": "2021-02-18",
      "has_results": false,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-10-01T05:03:43.599Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03936049"
    },
    {
      "nct_id": "NCT07223216",
      "title": "Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "BMF-650",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biomea Fusion Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2025-10-23",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-10-01T05:03:43.599Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07223216"
    },
    {
      "nct_id": "NCT02730377",
      "title": "Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "liraglutide",
          "type": "DRUG"
        },
        {
          "name": "alpha-glucosidase inhibitors",
          "type": "DRUG"
        },
        {
          "name": "DPP-4 inhibitors",
          "type": "DRUG"
        },
        {
          "name": "meglitinides",
          "type": "DRUG"
        },
        {
          "name": "SGLT-2 inhibitors",
          "type": "DRUG"
        },
        {
          "name": "sulphonylurea",
          "type": "DRUG"
        },
        {
          "name": "thiazolidinediones",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1991,
      "start_date": "2016-03-28",
      "completion_date": "2019-08-12",
      "has_results": true,
      "last_update_posted_date": "2020-07-07",
      "last_synced_at": "2026-10-01T05:03:43.599Z",
      "location_count": 179,
      "location_summary": "Birmingham, Alabama • Haleyville, Alabama • Tuscumbia, Alabama + 157 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Haleyville",
          "state": "Alabama"
        },
        {
          "city": "Tuscumbia",
          "state": "Alabama"
        },
        {
          "city": "Fountain Hills",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02730377"
    },
    {
      "nct_id": "NCT03426085",
      "title": "The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autonomic Nervous System Diseases",
        "Sweat Gland Diseases",
        "Diabetic Neuropathy With Neurologic Complication"
      ],
      "interventions": [
        {
          "name": "Liraglutide 6 mg Solution for Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eastern Virginia Medical School",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 44,
      "start_date": "2016-05",
      "completion_date": "2020-08",
      "has_results": false,
      "last_update_posted_date": "2019-02-11",
      "last_synced_at": "2026-10-01T05:03:43.599Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03426085"
    },
    {
      "nct_id": "NCT07224334",
      "title": "Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes (DM)"
      ],
      "interventions": [
        {
          "name": "Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David D'Alessio, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-12-30",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-10-01T05:03:43.599Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07224334"
    },
    {
      "nct_id": "NCT02647944",
      "title": "Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2015-12-18",
      "completion_date": "2016-12-30",
      "has_results": true,
      "last_update_posted_date": "2017-10-27",
      "last_synced_at": "2026-10-01T05:03:43.599Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02647944"
    },
    {
      "nct_id": "NCT07806838",
      "title": "Effects of Dietary Supplements on Muscle Mass and Function While Using GLP-1 Medication",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity & Overweight",
        "Muscle Mass and Strength",
        "Muscle Function"
      ],
      "interventions": [
        {
          "name": "Whey Protein Supplementation",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Maltodextrin Placebo Capsules",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Mixed Spice Capsules",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2026-09-10",
      "completion_date": "2028-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-10-01T05:03:43.599Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07806838"
    },
    {
      "nct_id": "NCT07527910",
      "title": "A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)"
      ],
      "interventions": [
        {
          "name": "ALN-PNP",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 204,
      "start_date": "2026-05-22",
      "completion_date": "2030-03-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-01T05:03:43.599Z",
      "location_count": 9,
      "location_summary": "Tucson, Arizona • Coronado, California • Pasadena, California + 6 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Jupiter",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07527910"
    },
    {
      "nct_id": "NCT06867718",
      "title": "Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity or Overweight"
      ],
      "interventions": [
        {
          "name": "RGT001-075",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regor Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 267,
      "start_date": "2025-01-24",
      "completion_date": "2025-11-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-10-01T05:03:43.599Z",
      "location_count": 35,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Huntington Park, California + 31 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06867718"
    },
    {
      "nct_id": "NCT04964388",
      "title": "Effect of GLP-1 Receptor Agonists on Trabecular Bone Score",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoporosis, Postmenopausal",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "GLP-1 receptor agonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Mississippi Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "55 Years and older · Female only"
      },
      "enrollment_count": 5,
      "start_date": "2021-11-09",
      "completion_date": "2023-07-01",
      "has_results": true,
      "last_update_posted_date": "2025-06-13",
      "last_synced_at": "2026-10-01T05:03:43.599Z",
      "location_count": 1,
      "location_summary": "Jackson, Mississippi",
      "locations": [
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04964388"
    }
  ]
}